Finanzen von Blueprint Medicines Corp (BPMC)BPMCBlueprint Medicines Corp

Blueprint Medicines Corp (BPMC) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Product revenue, accounting for 100.0% of total sales, equivalent to $128.18M. Another important revenue stream is Collaboration, license and other revenue. Understanding this composition is critical for investors evaluating how BPMC navigates market cycles within the Biotechnology & Medical Research industry.

Evaluating the bottom line, Blueprint Medicines Corp maintains a gross margin of 98.12%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -27.50%, while the net margin is 0.33%. These profitability ratios, combined with a Return on Equity (ROE) of -47.71%, provide a clear picture of how effectively BPMC converts its operational activities into shareholder value.

In the context of the broader market, BPMC competes directly with industry leaders such as TLX and TECH. With a market capitalization of N/A, it holds a significant position in the sector. When comparing efficiency, BPMC's gross margin of 98.12% stands against TLX's N/A and TECH's 67.25%. Such benchmarking helps identify whether Blueprint Medicines Corp is trading at a premium or discount relative to its financial performance.